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Background: The purpose of this study was to develop intraperitoneal hyperthermic therapy 
based on magnetic fluid hyperthermia, nanoparticle-wrapped cisplatin chemotherapy, and 
  magnetic particles of albumin. In addition, to combine the multiple-killing effects of   hyperthermal 
targeting therapy, chemotherapy, and radiotherapy, the albumin-nanoparticle surfaces were linked 
with radionuclide 188Re-labeled folic acid ligand (188Re-folate-CDDP/HSA).
Methods: Human serum albumin was labeled with 188Re using the pre-tin method. Reaction 
time and optimal conditions of labeling were investigated. The particles were intravenously 
injected into mice, which were sacrificed at different time points. Radioactivity per gram of 
tissue of percent injected dose (% ID/g) was measured in vital organs. The biodistribution of 
188Re-folate-CDDP/HAS magnetic nanoparticles was assessed.
Results: Optimal conditions for 188Re-labeled folate-conjugated albumin combined with cis-
platin magnetic nanoparticles were: 0.1 mL of sodium gluconate solution (0.3 mol/L), 0.1 mL 
of concentrated hydrochloric acid with dissolved stannous chloride (10 mg/mL), 0.04 mL of 
acetic acid buffer solution (pH 5, 0.2 mol/L), 30 mg of folate-conjugated albumin combined with 
cisplatin magnetic nanoparticles, and 188ReO4 eluent (0.1 mL). The rate of 188Re-folate-CDDP-
HSA magnetic nanoparticle formation exceeded 90%, and radiochemical purity exceeded 95%. 
The overall labeling rate was 83% in calf serum at 37°C. The major uptake tissues were the 
liver, kidney, intestine, and tumor after the 188Re-folate-CDDP/HSA magnetic nanoparticles were 
injected into nude mice. Uptake of 188Re-folate-CDDP/HSA magnetic nanoparticles increased 
gradually after injection, peaked at 8 hours with a value of 8.83 ± 1.71, and slowly decreased 
over 24 hours in vivo.
Conclusion: These results indicate that 188Re-folate-CDDP/HSA magnetic nanoparticles can 
be used in radionuclide-targeted cancer therapy. Surface-modified albumin nanoparticles with 
folic acid ligand-labeled radionuclide (188Re) were successfully prepared, laying the foundation 
for a triple-killing effect of thermotherapy, chemotherapy, and radiation therapy.
Keywords: cisplatin, folic acid, albumin, magnetic nanoparticles, 188Re, ovarian cancer
Introduction
Among the most common malignancies of the female reproductive organs, ovarian 
cancer occurs with the third highest incidence, second only to cervical and uterine 
carcinomas. However, ovarian cancer is the leading cause of death associated with 
gynecological malignancy. It is difficult to identify tissue types, and their benign or 
malignant nature, owing to the complexity of ovarian tissue, despite the ovary being 
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small in size. About 30% of ovarian cancers are found at 
an early stage, often during exploratory laparotomy and in 
the absence of overt symptoms. However, most (70%) of 
these tumors are at an end stage when first diagnosed, with 
metastasis to the uterus, annexes, greater omentum, and 
various organs in the pelvic cavity. Therefore, most patients 
miss their chance to get early treatment. Current treatment 
for ovarian cancer is mainly surgery in conjunction with 
chemotherapy and radiotherapy. End-stage ovarian cancer 
often recurs after treatment, and is extremely hard to treat. 
As a result, the 5-year survival rate is as low as 20%–30%.1 
Therefore, development of new therapeutic drugs and strate-
gies has practical relevance.
Thermotherapy is a method of treating tumor tissue using 
heat generated by various physical energies in human tissues 
to raise and maintain a cell temperature higher than 40°C for 
a period of time sufficient to kill cancer cells while avoiding 
damage to normal cells. During the past 20 years, with the 
developments in biology, physics, and medical technology, 
both the theories and techniques of thermotherapy have been 
advanced rapidly. Among the various heating methods that 
have been developed, microwave, radiofrequency, and ultra-
sonic waves are standard methods with obvious therapeutic 
effects in both superficial and luminal tumors. However, due 
to partial reflection of electromagnetic waves by the body 
contour and the electric properties of human tissue, it is dif-
ficult for the energy of electromagnetic waves to concentrate 
in the deep tumor layers. This may cause nonuniform heat 
distribution.2,3 In addition, it is hard to measure and maintain 
a constant temperature accurately at the deeper layers, which 
also limits the application of thermotherapy in the treatment 
of cancer.
Usually metastasizing via local spread and abdominal 
seeding, ovarian cancer is thermosensitive. It tends to local-
ize in the abdominal cavity, even at end stage, and thus is 
suitable for treatment with intraperitoneal chemohyper-
thermia. This technique was first used in the clinic by Spratt 
et al in 1980. The strategy is to combine high temperature 
and chemotherapy to eliminate free cancer cells and small 
residual cancerous lesions in the abdominal cavity in order 
to prevent or reduce local postoperative recurrence and 
metastasis. Recently, intraperitoneal chemohyperthermia has 
attracted further attention and been widely used throughout 
the world, achieving satisfactory therapeutic outcomes.4–6 
The National Cancer Research Institute in Italy has carried 
out stage II testing of intraperitoneal chemohyperthermia 
  (cisplatin +   mitomycin C) in 27 cases of recurrent ovarian 
cancer, and the two-year survival rate was 55%, with a median 
time to local tumor progression of 21.8 months. Of note, a 
stage III study of 415 patients with end-stage ovarian cancer 
showed that the median survival time in patients treated with 
combined chemotherapy via the venous and abdominal cavity 
routes was 65.6 months, while that of patients who received 
only intravenous chemotherapy was 49.7 months.7 The results 
of this study were considered to represent major progress in 
clinical gynecological oncology in 2006 by the American 
Society of Clinical Oncology. The US National Cancer 
Research Institute has also made a statement recommend-
ing that such patients should be treated with chemotherapy 
delivered by both the venous and abdominal cavity routes. 
However, because intraperitoneal chemohyperthermia is an 
invasive method, and both targeted chemotherapy and thermo-
therapy have some disadvantages, adverse effects are inevi-
table. In addition, many complications have occurred when 
intraperitoneal chemohyperthermia has been used clinically, 
including intestinal obstruction,8 anastomotic leakage8,9 renal 
damage,9 and bone marrow inhibition,10,11 which has limited 
the wider clinical application of this technology. The National 
Surgical Adjuvant Breast and Bowel Project and American 
College of Surgeons Oncology Group have organized several 
research programs to address some of the fundamental prob-
lems of intraperitoneal chemohyperthermia, in particular to 
improve the heating equipment and methods used to measure 
and maintain deep layer temperature accurately, to increase 
the effective target orientation, and decrease the side effects 
of chemotherapy.
The concept of magnetic targeted chemotherapy was 
proposed by Gilchrist et al in 1957.11 Magnetic materials 
in the circulation can not only reach the target13 precisely 
under the influence of an applied static magnetic field but 
can also absorb electromagnetic wave energy and generate 
heat to control and maintain temperature within the required 
range (42°C–46°C) for a period of time sufficient to destroy 
cancer tissue and avoid damage to normal tissues outside 
the target area under the alternative magnetic field. A novel 
nanotechnology method combined with thermotherapy was 
used by Jordan et al in Germany14–16 to treat tumor tissue, 
which was a major step forward. Fluid containing magnetic 
nanoparticles was injected into the transplanted tumors of 
breast cancer-bearing C3H mice. When locally radiated in an 
alternative magnetic field, the magnetic particles absorbed 
energy and the temperature rose to 47°C. As a result, the 
tumor was controlled effectively. This new method is called 
magnetic fluid heating. Acted on by an alternative magnetic 
field, the magnetic nanoparticles can absorb more energy and 
generate more heat than microparticles, leading to a better 
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thermotherapeutic effect and a more uniform increase in 
temperature. Jordan et al also found that the ability of tumor 
cells to absorb ferrous nanoparticles is 8–400 times that of 
normal cells, and that the tumor cells still contained mag-
netic nanoparticles during division. Quantitative analysis by 
electron microscopy showed that descendant cells contained 
on average 50% of the magnetic nanoparticles contained 
by the parent cells. Tumor cells containing these magnetic 
nanoparticles can be destroyed easily by magnetic fluid heat-
ing. According to the literature, magnetic fluid heating has 
several important characteristics.17 First, it has the effect of 
being a “thermal onlooker.” When magnetic fluid is applied 
to the tumor, the magnetic particles are diffusely and homo-
geneously acted upon by the alternative magnetic field, and 
the volume radiated gradually increases, killing tumor cells 
in the area containing the magnetic nanoparticles. Second, 
magnetic fluid heating is a nonactive material with high 
biological compatibility. Third, the therapeutic effect results 
from a physical conversion (ie, the alternative magnetic field 
generates heat). Fourth, the high temperature reached can 
increase the effects of chemotherapy and radiotherapy. The 
most recent studies18 have shown that a constant tempera-
ture can be maintained automatically for thermotherapy by 
using ferromagnetic materials, based on the fact that these 
materials have magnetic properties and produce heat only 
when the temperature is lower than the Curie point. Once 
the temperature rises above the Curie point, they lose their 
magnetic properties and the temperature increase stops. This 
avoids any nonuniform uncontrolled temperature rise, which 
is important when thermotherapy is applied to the deeper 
layers of tumor tissue. Therefore, identification of a suitable 
magnetic induction material for magnetic fluid heating has 
become a hot topic in this area of research.19
A modified chemical coprecipitation method was initially 
used to prepare nanometric MnxZn1–xFe2O4 as a magnetic 
induction material for magnetic fluid heating to treat liver 
and cervical cancers, with satisfactory outcomes.20,21 The 
ratio of Mn and Zn was adjusted to provide a specific Curie 
point.22,23 This material is strongly magnetic when below 
the Curie point, absorbing electromagnetic waves from the 
alternative magnetic field, causing a temperature rise. When 
the temperature reaches the Curie point, the material becomes 
nonmagnetic and loses its ability to absorb electromagnetic 
waves, and the temperature decreases. When the temperature 
is below the Curie point, it recovers its magnetic properties 
and the temperature rises again. Temperature can now be 
controlled at a set Curie point, so the problems of lack of 
automatic temperature control and constant temperature in 
thermotherapy are resolved, and the stability and safety of 
thermotherapy has improved. Biological compatibility and 
safety are important prerequisites in the clinical setting,24 and 
studies of self-assembled Mn-Zn ferrite in this regard have 
had encouraging results.25
Binding of a receptor to its ligand is characterized by 
specificity, selectivity, saturation, strong affinity, and obvi-
ous biological effects. So far, one of the most active fields 
of study is the use ligands as carriers of drugs or radio-
nuclides for targeted treatment, ie, increasing local drug 
concentrations in lesions via conductivity of the receptor in 
media, and improving the therapeutic effect while reducing 
 toxicity. With better understanding of the folic acid recep-
tor, it has been found that the activity and quantity of folic 
acid receptors on the membrane surface of various tumor 
cells (including ovarian, colorectal, breast, lung, and renal) 
is significantly higher than that of normal cells, which has 
laid the foundations for investigating folic acid as a targeted 
treatment for cancer.26 Albumin contains abundant lysines, 
which account for about 10% of its total number of amino 
acids. Exposed lysine ε-amino and terminal amino groups 
on the surface of albumin nanoparticles (surface-reactive 
amino groups) are targets for effective chemical modifica-
tion. For this reason, human serum albumin (HSA) nano-
particles have been coupled with the active ester of folic 
acid, used to target these surface-reactive amino groups, 
and their efficacy explored under different conditions. The 
rationale of this research was to exploit the high folic acid 
receptor expression on the surface of various tumor cells, 
thereby enabling targeted and enhanced uptake of albumin 
nanoparticles by tumor tissue.27 After optimization of the 
experimental conditions, it was clearly seen on dextran gel 
column chromatography that folic acid-coupled albumin 
nanoparticles were totally separated from the active ester 
of folic acid, and the hydrolysate of trypsin in a mechanical 
mixture of folic acid coupled-albumin nanoparticles showed 
an ultraviolet absorption peak at 358 nm, demonstrating that 
folic acid had successfully coupled onto the surface of the 
albumin nanoparticles.
Because albumin nanoparticles are excellent carriers of 
radioactive nuclides, temperature can be used to enhance the 
efficiency of the rays, and synergism of various therapeutic 
methods is a trend in tumor treatment. The present study 
used  188Re to achieve the triple-killing effect of targeted 
thermotherapy, chemotherapy, and radiotherapy.
Compared with related studies in China and other coun-
tries, our study was unique in using albumin nanoparticles as 
the carrier, the folic acid receptor as the target, and combining 
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chemotherapy, thermotherapy, and radionuclide therapy. It 
has solved not only the problems of automatic temperature 
control, but also combined the orientated killing effect of 
chemotherapy and nuclear radiation. This technique meets 
the requirements of safety, effectiveness, and specificity 
which are critical for any new biotherapeutic method being 
applied in the clinical setting.
Materials and methods
Instrumentation
The instruments used were a 188W/188Re generator   (Shanghai 
Kexin Company, Shanghai, China), JA1003 electronic 
balance (Shanghai Balance Instrument Factory, Shanghai, 
China), GC911 gamma radioimmune counter (Zhongjia 
  Photoelectric Instrument Branch Company General Company 
of Scitech Industry, China Scitech University, Zhejiang, 
China), GF-1 high speed disperser (Jiangsu Haimen Qilin 
Medical Instrument Factory, Jiangsu, China), DMC-1 direct 
current constant speed mixer (Shanghai Sile Instrument 
  Factory, Shanghai, China), 34-061 activity meter (Victoreen 
Company, Cleveland, OH).
Pharmaceuticals and reagents
Human serum albumin (Shanghai Shenggong Biotech 
  Company Ltd, Shanghai, China), SnC12 ⋅ 2H2O, sodium 
gluconate, acetic acid, acetate sodium, absolute alcohol, 
hydrochloric acid, and sodium hydroxide are all obtained 
as analytical pure reagents.
Preparation of 188Re-folate-CDDP/HSA 
magnetic nanoparticles
188ReO4
− cleansing solution was obtained using a 88W/188Re 
generator (Shanghai Kexin Company) and was used directly 
for labeling without purification. The labeling process was 
as follows: 0.1 mL sodium gluconate solution (0.3 mol/L), 
0.1 mL stannous chloride dissolved in strong hydrochloric 
acid (10 mg/mL), 0.04 mL acetic acid buffer solution (pH 5.0, 
0.2 mol/L), and 30 mg folate-CDDP/HSA magnetic nano-
particles in a centrifuge tube.27 The mixture was then shaken 
and kept at room temperature for one hour. A 0.1 mL sample 
of 188ReO4
− cleansing solution was added and shaken for five 
hours at room temperature to complete the labeling.
Determination of labeling rate
A thin-layer hierarchical analytic procedure was used. 
A GF254 silica gel plate was selected as the supporting mate-
rial and baked at 56°C in an air oven for 30 minutes before 
use. The silica gel plate was cut into 0.5 cm × 10 cm pieces 
and a primary point was marked with a pencil 1 cm away 
from the bottom edge of the test paper. Ten lateral equidistant 
lines were drawn with a pencil, and 10 checks were reserved 
for use. A test tube was taken and checked, and a develop-
ing agent was added, comprising alcohol:ammonia:water 
(2:1:5 v/v). A capillary tube was used to suction the labeled 
188Re-folate-CDDP/HSA magnetic nanoparticles from an 
Eppendorf tube, which were dropped at the primary point, 
dried, and then analyzed using the hierarchical analytic pro-
cedure. The analytic paper was taken out, dried, cut into 10 
pieces as per the drawn checks, and the pieces were put into 
a polyethylene test tube to determine radioactivity (radio-
frequency was 0 for the gel labeled with 188Re and 0.7–0.8 
for the 188Re-folate-CDDP/HSA magnetic nanoparticles and 
188ReO4
−). The radioactive distribution for each analytic paper 
was determined, and the labeling rate was measured using 
the following formulae:
Radiofrequency = Distance between component to be tested 
and primary point/distance between   frontal mobile phase 
and primary point
Labeling rate (%) = Sum of radioactive counting rate of 
labeled material/total radioactive   counting rate × 100%.
Determination of the radiochemical purity of the 188Re-
folate-CDDP/HSA magnetic nanoparticles was done using 
the following methods.
Optimization of labeling conditions  
for 188Re-folate-CDDP/HSA nanoparticles
The relationship between the various parameters and label-
ing rate was investigated by determination of labeling rate 
when changing one parameter of the labeling conditions 
while leaving the other parameters unchanged. Labeling 
rates were determined under different conditions to obtain 
optimum labeling:
•  Radiochemical purity at 1, 2, 3, 4, 5 and 6 hours after 
labeling
•  pH value of the acetic acid buffer solution 4.0–6.0
•  Volume of cleansing solution 50–200 µL
•  Volume of stannous chloride 50–1500 µg
•  Labeling material reacted at room temperature or in a 
37°C water bath for 5 hours.
In vitro stability of 188Re-folate-CDDP/HSA 
nanoparticles
The labeled magnetic nanoparticles were washed twice with 
distilled water and normal saline, and were then dispersed in 
1 mL of calf serum, oscillated and incubated at 37°C, with 
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sampling at 0, 2, 4, 8, 12, 24, 48 and 72 hours. Radioactive 
counting was then performed.
Experimental animals
Twenty-one female BALB/C nude mice, aged 4 weeks and 
weighing 15–19 g, were obtained from the Experimental 
Animal Center at Jiangsu Institute of Nuclear Medicine.
Tumor cell culture
Human ovarian cancer SKOV3 cells were supplied by the 
Shanghai China Typical Cell Culture Collection Center. 
Routine culture and generation of next-generation human 
ovarian cancer SKOV3 cells were carried out in 5% CO2 
and at 37°C in an air oven with calf serum 10%, penicillin 
100 U/mL, streptomycin 100 mg/mL, insulin 40 U, and 
McCoy’s 5A culture medium with a pH of 7.4.
Tumor-bearing nude mouse model
Human ovarian cancer SKOV3 cells were implanted 
under the skin on the right side in 21 BALB/C nude mice. 
The inoculation volume was 0.1 mL (concentration of 
living cells 1 × 107/mL). After inoculation, tumor nodes 
appeared at the inoculated site, which were observed con-
tinuously for 2 weeks. Tumors were judged to have formed 
from the appearance of hard tumor nodes at the inoculated 
site and increasing nodal enlargement. The mice were 
raised in an appropriate animal house, and fed with cool 
boiled water and fodder sterilized with steam. The wood 
chips used for bedding were sterilized with steam, and the 
mouse cages were sterilized with a disinfectant   solution. 
Water, fodder, wood chips, and cages were changed and 
cleaned once a day, ambient temperature was kept at 
22°C ± 1°C and humidity at 60% ± 10%, on a 12-hour 
day/night cycle. Maximum tumor diameter was measured 
using a vernier caliper.
Biodistribution of 188Re-folate-CDDP/HSA 
magnetic nanoparticles
All animal experiments were carried out in compliance with 
national laws relating to animal research. The 21 BALB/C 
tumor-bearing nude mice were randomized into seven groups, 
with three mice in each group.  188Re-folate-CDDP/HSA 
magnetic nanoparticles (0.74 MBq/0.2 mL) were injected 
into the tail veins of the mice in each group. The mice were 
then sacrificed by cervical dislocation at 0.5, 1, 2, 4, 8, 24, and 
48 hours after injection. Blood, brain, heart, liver, spleen, lung, 
kidney, stomach, small intestine, muscle, ovary, pancreas, gall 
bladder, and tumor were removed for measurement of weight, 
radioactivity count, and percentage of injected volume per 
gram (% ID/G) after radioactive decay was calculated.
Statistical analysis
SPSS version 3.0 (SPSS Inc, Chicago, IL) was used for t-  testing 
and single-factor analysis of variance. Numerical data were 
expressed as the mean ± standard deviation. A P value ,0.05 
was considered to be statistically significant.
Results
Influence of reaction time on 
radiochemical purity
Changes in radiochemical purity were measured at 1, 2, 3, 
4, 5 and 6 hours after labeling, and the results are shown in 
Figure 1. Radiochemical purity increased with prolonging of 
the reaction time and reached 92.39% ± 3.86% after 5 hours 
versus 78.67% ± 5.57% after 4 hours. This difference was 
statistically significant (n = 3, 0.01 , P , 0.05).
Influence of pH buffer solution on 
radiochemical purity
When other conditions were kept constant and the pH of the 
buffer solution was changed, radiochemical purity . 85% was 
achieved when the pH was 4.0–5.5, and was 94.6% ± 2.67% 
when the pH was 5.0. This difference was statistically sig-
nificant (n = 3, P , 0.01) compared with 75.4% ± 3.56%   
when pH was 6.0. The results are shown in Figure 2.
Influence of cleansing solution volume on 
radiochemical purity
When other conditions were kept constant and the 
cleansing solution volume was changed, radiochemi-
cal purity was .85% when the volume was 100–200 µL 
and 75.8% ± 4.93% when the volume was 250 µL 
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Figure 1 Influence of reaction time on radiochemical purity.
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(  Figure 3). This difference was statistically significant (n = 3, 
0.01 , P , 0.05) compared with a radiochemical purity of 
92.7% + 5.19% when the volume was 150 µL.
Influence of SnC12 ⋅ 2H2O use on 
radiochemical purity
When other conditions were kept constant and the concentrations 
of SnC12 ⋅ 2H2O were changed, radiochemical purity .90%   
was obtained with a higher volume of SnC12 ⋅ 2H2O (.1000 µg, 
see Figure 4). Radiochemical purity was ,70% at 500 µg of 
SnC12 ⋅ 2H2O, and was 61.46% ± 3.56% and 92.51% ± 4.72% 
at 500 µg and 1000 µg of SnC12 ⋅ 2H2O, respectively. This dif-
ference was statistically significant (n = 3, P , 0.01). The gel 
content was lower than 10% in all labeled reactions.
Influence of reaction temperature on 
radiochemical purity
The effect of reaction temperature was compared between 
room temperature and a 37°C water bath for 5 hours, 
giving a radiochemical purity of 95.78% ± 1.61% and 
95.96% ± 1.32%, respectively. The difference was not sta-
tistically significant (n = 3, P . 0.05).
In vitro stability
Radiochemical purity of 188Re-folate-CDDP/HSA magnetic 
nanoparticles in calf serum was 95.57% ± 0.09% at 37°C, 
and values were stable over 2, 4, 8, 12, 24, 48, and 72 hours, 
being 95.29% ± 1.00%, 94.65% ± 0.78%, 91.26% ± 0.99%, 
88.53% ± 0.91%, 85.2% ± 0.7%, 83.38% ± 0.22%, and 
80.30% ± 0.11%, respectively (Figure 5).
Tumor growth in nude mice
Two weeks after inoculation with the tumor cells, nodes 
appeared under the skin at the inoculated site. These grew 
larger, were round or oval, protruded above the skin surface, 
and the skin on the tumor surface became thinner, semitrans-
parent, and smooth. After 3 weeks, the tumor diameter was 
about 0.5 cm.
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Figure 2 Influence of pH of buffer solution on radiochemical purity.
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20
10
40
30
50
60
80
90
70
100
0 500 1000
R
a
d
i
o
c
h
e
m
i
c
a
l
 
p
u
r
i
t
y
 
(
%
)
1500 2000
SnC12·2H2O (µg) 
Figure 4 Influence of SnC12 ⋅ 2H2O concentration on radiochemical purity.
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Figure 5 Stability of 188Re-folate-CDDP/HSA magnetic nanoparticles in calf serum.
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Biodistribution of 188Re-folate-CDDP/
HSA magnetic nanoparticles
The distribution of  188Re-folate-CDDP/HSA magnetic 
nanoparticles in the organs and tumor tissues of the 
tumor-bearing nude mice is shown in Table 1. It can be 
seen that the 188Re-folate-CDDP/HSA magnetic nanopar-
ticles injected via the tail vein were distributed mainly in 
the liver, kidney, stomach, intestine, and tumor tissue. The 
radioactivity in blood decreased rapidly after injection, 
and in vivo radioactivity was not detectable after 24 hours. 
Radioactivity of the tumor tissues reached a peak value of 
7.86% ± 0.91% ID/g at 8 hours, at which time the radio-
active ratio of tumor to opposite muscle also reached a 
maximum of 8.83 ± 1.71.
Discussion
Radiotherapy destroys or injures tumor cells by introducing 
radioactive nuclides into the tumor. The radioactive nuclides 
used include alpha or beta particles, Auger electrons, and 
internal conversion electrons. 188Re, obtained by a 188W/188Re 
generator, has excellent nuclear properties, with a physical 
half-life of 16.9 hours.28 It mainly transmits beta-rays for 
tumor treatment, with a ray energy of 2.11 MeV (79%) 
and 1.97 MeV (20%). It also transmits 155 keV gamma 
rays suitable for imaging. A radioactive detector outside 
the body can be used for tracing and imaging. 188Re and its 
labeled compound have clear therapeutic effects in tumor 
tissue, synovial membranes in the joints, and postoperative 
arterial stenosis, with minor side effects. With a high linear 
density of energy transmission, it can also kill distant tumor 
cells and tumor cells at the nonproliferation stage where 
chemotherapy fails, so is widely used as a component in 
radioactive agents.29
Direct labeling or chelatometry can be used to label 
188Re on HSA. Chelatometry uses a dual-function chelant 
to connect  188Re with amino acids in a protein molecule. 
The chelant should be linked to the protein molecule before 
labeling. Direct labeling methods include the pre-tin method 
and the stepwise reduction method. This study used the 
pre-tin method for direct labeling of 188Re on HSA. There 
are several possible explanations for this labeling method.23 
First, the reducing agent (SnCl2) opens the bisulfur bond 
on the protein molecule, exposing the sulfhydryl group of 
cysteine in the protein, which combines with SnCl2 to form 
a compound. Second, the valence state of 188Re is reduced by 
SnCl2 and a medium ligand forms the chelate. Third, 188Re in 
the chelate is displaced to the sulfhydryl group of cysteine 
in the protein molecule.
The electrode potential of 188ReO−
4 is relatively low and 
difficult to reduce. While it is helpful to reduce 188ReO−
4, a 
high concentration of SnCl2 is easy to react with Re in the 
system to form Re-Sn gel. Rhodes reported30 that about 4% 
of the bisulfur bonds in the protein molecule are reduced. 
During reduction, only the outer bisulfur bonds should be 
reduced, and not involve the main bisulfur bonds which main-
tain the structural integrity of the protein molecule. Using 
acetic acid buffer solution to adjust the pH of the reaction 
system is easier than using sodium hydroxide. When the pH 
is lower than 4.0, it will affect the bioactivity of the label. 
188Re (V) will reoxidize to 188ReO−
4 when the pH is higher 
than 5.5. When the pH is 4.5–5.0, it can prevent formation 
of insoluble oxides of tin and Re.25 When the cleansing 
Table 1 Biodistribution of 188Re-folate-CDDP/HSA magnetic nanoparticles in mice with a gamma counter
Organ Time after injection (hours)
0.5 1 2 4 8 24 48
Blood 2.41 ± 0.75 1.70 ± 0.36 1.92 ± 0.51 1.94 ± 0.32 2.83 ± 2.15 0.38 ± 0.16 0.30 ± 0.17
Brain 0.19 ± 0.04 0.10 ± 0.02 0.09 ± 0.04 0.09 ± 0.03 0.08 ± 0.04 0.05 ± 0.01 0.03 ± 0.01
Heart 0.98 ± 0.43 1.55 ± 0.46 0.68 ± 0.21 0.72 ± 0.13 0.49 ± 0.17 0.09 ± 0.03 0.14 ± 0.01
Liver 4.48 ± 1.93 2.18 ± 0.91 1.67 ± 1.20 2.17 ± 0.83 1.65 ± 0.41 0.69 ± 0.15 0.55 ± 0.03
Spleen 2.68 ± 1.05 1.88 ± 0.52 1.66 ± 0.43 1.39 ± 0.34 2.68 ± 0.61 0.58 ± 0.13 0.38 ± 0.02
Lung 2.07 ± 0.81 1.59 ± 0.37 1.88 ± 0.61 1.68 ± 0.38 0.99 ± 0.47 0.48 ± 0.23 0.43 ± 0.22
Kidney 2.19 ± 0.40 1.28 ± 0.17 1.45 ± 0.29 1.37 ± 0.30 0.87 ± 0.32 0.16 ± 0.03 0.15 ± 0.01
Stomach 5.78 ± 3.50 3.76 ± 1.51 7.49 ± 1.20 9.59 ± 1.93 5.81 ± 2.38 0.27 ± 0.03 0.15 ± 0.03
Small intestine 2.28 ± 0.51 2.09 ± 0.61 2.88 ± 1.03 3.08 ± 1.31 1.99 ± 1.44 0.18 ± 0.10 0.12 ± 0.02
Contralateral muscle 0.55 ± 0.33 0.48 ± 0.05 1.11 ± 0.73 0.58 ± 0.10 0.89 ± 0.43 0.14 ± 0.03 0.16 ± 0.03
Ovaries 1.27 ± 0.38 0.49 ± 0.07 0.88 ± 0.45 0.79 ± 0.13 0.68 ± 0.27 0.16 ± 0.09 0.19 ± 0.16
Pancreas 1.25 ± 0.52 0.59 ± 0.20 0.98 ± 0.48 1.36 ± 0.33 0.69 ± 0.26 0.15 ± 0.04 0.09 ± 0.01
Bladder 1.95 ± 0.22 0.89 ± 0.61 1.39 ± 0.78 2.35 ± 1.12 1.85 ± 1.42 0.49 ± 0.27 0.33 ± 0.02
Tumor 2.15 ± 1.43 2.18 ± 0.57 2.58 ± 0.23 3.44 ± 0.45 7.86 ± 0.91 0.79 ± 0.24 0.20 ± 0.01
Notes: Values are expressed as % ID/g (percent of injected dose per gram tissue). Data are presented as the mean ± standard deviation.
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solution volume is small, the radiochemical purity increases 
with an increasing volume of cleansing solution, but when 
the cleansing solution volume increases beyond a certain 
level, the concentrations of 188Re and the labeled substrate 
in the reaction system decrease correspondingly, resulting in 
decreased radiochemical purity. Radiochemical purity at an 
ambient temperature of 22°C or in a 37°C water bath was not 
significantly different. Because labeling of the polypeptide 
at ambient temperature is ideal, a temperature of 22°C was 
selected for labeling. In this study, the labeling rate for the 
prepared  188Re-folate-CDDP/HSA magnetic nanoparticles 
was over 90%, and their radiochemical purity was over 95%. 
Labeling done in calf serum at 37°C yielded a labeling rate 
of 83% at 72 hours, which is suitable for clinical use. The 
188Re-folate-CDDP/HSA magnetic nanoparticles was then 
injected into tumor-bearing nude mice through the tail vein. 
Because the activity and quantity of folic acid receptors on the 
surface of the ovarian cancer cell membrane is significantly 
higher than that on normal cells, folic acid coupled to the 
albumin surface of the nanoparticles binds specifically with 
the folic acid receptor on the surface of the ovarian cancer cell 
membrane. Meanwhile, the radionuclide on the carrier acts 
on tumor cells specifically, playing a targeting role, resides 
in tumor cells for a long time, delivering a higher radiation 
dose to the tumor tissue. These nanoparticles can also kill 
or injure tumor cells around the target area, and in this way, 
the tumor-suppressing effect is increased.
In the present study, after the 188Re-folate-CDDP/HSA 
magnetic nanoparticles were injected into tumor-bearing 
nude mice, they were widely distributed in different tissues 
and organs, and the tissue concentration and distribution 
decreased with time.  188Re-folate-CDDP/HSA magnetic 
nanoparticles were taken up in significant amounts by the 
stomach, followed by the liver and small intestine. Compared 
with the liver, the concentration in the kidney was less, indi-
cating that 188Re-folate-CDDP/HSA magnetic nanoparticles 
may be less toxic to the liver, helping to mitigate hepatic 
metabolism of cancer chemotherapy and the burden on the 
kidney. Our results indicate that  188Re-folate-CDDP/HSA 
magnetic nanoparticles underwent predominantly digestive 
metabolism after injection into mice. A significant amount 
of radioactivity was cleared from the body by 24 hours, 
but further study of clearance is needed. Tumoral uptake of 
188Re-folate-CDDP/HSA magnetic nanoparticles reached a 
peak at 8 hours of 7.86 ± 0.91 (% ID/g), the ratio of tumor/
muscle increased gradually after injection, reaching a maxi-
mum of 8.83 ± 1.71 at 8 hours, then decreased gradually, and 
radioactivity in vivo appeared to be eliminated at 24 hours. 
It is suggested that  188Re-folate-CDDP/HSA magnetic 
nanoparticles could be used as radionuclide targeted treat-
ment for tumors.
Our results also suggest that  188Re-folate-CDDP/HSA 
magnetic nanoparticles are distributed in nontarget organs 
and for a longer duration by intravenous administration, 
which may result in radioactive organ damage, especially in 
the liver, kidney, and gastrointestinal tract, and this may be an 
important issue in the targeted radionuclide treatment of can-
cer. The issue is expected to be resolved by using appropriate 
methods to reduce the normal organ uptake of radionuclides 
and to speed up their metabolism. Ingestion of a fatty meal 
can limit the excessive uptake of 188Re-folate-CDDP/HSA 
magnetic nanoparticles in the stomach. Percutaneous intra-
tumoral injection of  188Re-folate-CDDP/HSA magnetic 
nanoparticles may also be a useful method by which to reduce 
radiation damage to normal tissues and organs, enabling the 
radionuclides to remain in the tumor tissue, and also plays 
a role as a tumor marker. Direct percutaneous intratumoral 
injection in solid tumors is a promising route of administra-
tion and requires further research in the future.
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